BMS, Pfizer win patent dispute over blockbuster drug, Eliquis
06-09-2021
BMS sues Mylan to block Reyataz generic
20-03-2015
clu / iStockphoto.com
Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Teva, Bristol-Myers Squibb, Pfizer, Abbreviated New Drug Application, US District Court for the District of Delaware, generics
